Contact

 

Dr. Marc S. Raab
Phone: +49 6221 421450

E-mail: m.raab@dkfz.de

Personalizing therapies ...

 

in hematology to improve patient outcome.

Experimental Therapies for Hematologic Malignancies

DKFZ
 
 
 

Our group/department has:

The group of Marc S. Raab is focused on the discovery of new therapeutic targets, investigating new treatment strategies, and ultimately improve patient outcome in our model disease, multiple myeloma. To this end the group has:

  • Demonstrated that centrosomal clustering is a specific therapeutic approach in cancer (Raab et al. Cancer Res 2012)
  • Revealed the clinical and therapeutic significance of the BRAF V600E mutation in multiple myeloma  - the first personalized treatment in this disease (Andrulis et al. Cancer Discovery 2013)
  • Initiated a translational program to personalize therapy for refractory myeloma

2010 – 2013

  • Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013 Aug;3(8):862-9.
  • Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Krämer A. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res. 2012 Oct 15;72(20):5374-85.
  • Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013 Dec 1;31(34):4325-32
  • The group is substantially supported by the Max-Eder-program of Deutsche Krebshilfe, among others.